uniQure shares slide 41% after AMT-130 Huntington’s data miss significance at 48 months
AI Market Summary
uniQure's AMT-130 48-month update missed statistical significance on the key cUHDRS measure, with the implied slowing dropping from 75% at 36 months to 44%, triggering a sharp selloff and raising execution/regulatory uncertainty around its accelerated approval filing. While management and analysts highlighted comparator-data issues and a steady TFC secondary endpoint, near-term sentiment is pressured by weaker primary-readout optics and higher scrutiny of the evidence base.
Impact level
● Medium
Affected assets
NCSKCRDO2USD/USDT+4.27%
AI Insight · NCSKCRDO2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
uniQure released 48-month clinical data for its Huntington’s disease gene therapy AMT-130 that did not significantly slow disease progression. The cUHDRS measure showed the slowdown easing to 44% at month 48 from 75% at month 36. The stock fell 41% at the open to $23.15. Analysts and company executives said they remain encouraged by the strength of a secondary endpoint and still see a potential path to approval.
